Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)
Ascendiant Capital維持對novabay製藥的買入評級，將價格目標調整爲0.85美元（1-35股票逆向拆分）
Ascendiant Capital analyst Edward Woo maintains NovaBay Pharmaceuticals (AMEX:NBY) with a Buy, adjusts target to $0.85 from $8 (1-35 Reverse Stock Split).
Ascendiant Capital分析師Edward Woo維持買入評級novabay pharmaceuticals(AMEX:NBY)，調高目標價至$0.85，由$8調整（1-35股票逆向拆股）。
資訊熱榜
更新時間